Tumori

Trends in cancer mortality in Spain: 1975-2004

Milagros Bernal, Franchesco J Gómez, German Gómez

¹Preventive Medicine, Faculty of Medicine, Zaragoza; ²Family Doctor, Zaragoza;
³Psychiatry Department, University of Zaragoza, Spain

Key words: cancer mortality, joinpoint analysis, Spain, trends.

abstract

Aims and background. Total cancer mortality rates in the European Union have declined by about 7% over the period 1982-2002. The aim of the present study was to investigate similar trends in Spain over the period 1975 to 2004 by age, sex, and cancer site.

Patients and methods. Trends in Spanish mortality rates (standardized to the world standard population) for all cancers and for 14 major cancer sites for the years 1975 to 2004 are analyzed. Join point regression analysis was used to identify points where a significant change in trend occurred.

Results. The overall cancer mortality rate in Spain in men and women declined by about 1% a year between 1995 and 2004. For the period 1975 to 2004, declines were observed for several neoplasms: lip, -3.62% in men and -3.39% in women; esophagus, -0.28% in men and -2.73% in women; stomach, -2.99% in men and -3.66% in women; liver, -0.52% in men and -3.77% in women. There was a substantial rise in: colon cancer, 3.72% in men and 1.79% in women; pancreas, 2.21% in men and 2.25% in women; lung cancer rose 1.18% in men and 0.97% in women, and between 1999-2004 it rose 5.23% in women. Most of these are tobacco-related neoplasms.

Conclusions. Cancer mortality in Spain is mainly a tobacco-related problem. More attention needs to be focused on campaigns to decrease and prevent smoking, especially in the young, where smoking rates are higher than in the general population.

Introduction

Total cancer mortality rates in the European Union and other developed countries have seen a steady decline over the past 20 years, with similar trends occurring in Spain. However, cancer remains a major problem in Spain and is the leading cause of death among Spanish men and the second leading cause among Spanish women. For both men and women between the ages of 40 and 79, it is the leading cause of death, exceeding cardiovascular disease and stroke. Therefore, it is important to provide updated information on cancer mortality in Spain and to identify the major tissues contributing to Spanish cancer deaths.

Using official cancer mortality rates in Spain for the years 1975 to 2004, we provide annual mortality rates (adjusted to the world standard population) for all cancers and for 14 major cancer sites. Since long-term trends provide useful information to understand recent patterns and to project most likely future trends, the major aim of the present work is to provide comprehensive documentation on the patterns of cancer mortality trends in Spain.

Materials and methods

Official death-certification numbers for all cancers and for major cancer sites were derived from the official Spanish data base¹. The classification of cancer deaths was recorded for all calendar periods according to the ICD ninth revision. Estimates of the resident population, generally based on official censuses, were obtained from the official dates from matrices of certified deaths and resident populations, age-specific rates for each 5-year age group and age-standardized rates per 100,000 population². All ages were computed using the direct method based on the world standard population.

Annual percentage changes in rates were computed using a joinpoint log-linear model³ (Figures 1 and 2). Joinpoint is a statistical software package for the analysis of trends using joinpoint models, that is to say, models where several different straight lines meet at “joinpoints.” The program starts with the minimum number of joinpoints and tests whether more joinpoints are statistically significant and must be added to the model. This enables the user to test whether an apparent change in trend is statistically significant. The test of significance uses a Monte Carlo Permutation method. The models may incorporate estimated variation for each point or use a Poisson model of variation. In addition, the models may also be linear on the log of the response (the calculation of annual percentage rate change). The software also enables us to view one graph for each joinpoint model, from the model with the minimum number of joinpoints to the model with the maximum number of joinpoints.

Results

Overall cancer mortality rates in Spain have declined significantly in recent years. After increasing from 1975 to 1995, cancer mortality in man has decreased by about 1% per year since 1995. Cancer mortality in women decreased from 1975 to 1985, remained fairly constant until 1995, and then similar to men, declined at about 1% per year. Table 1 and Figures 1 and 2 provide corresponding changes in rates in both sexes.

Divided into sexes, the following was observed: In men, cancers that decreased the most were, per year, lip cancer (-3.62%), stomach cancer (-2.99%) and testicular cancer (-2.45%). The model enabled us to establish the different percentages of change so that: for lip cancer, whose fall has remained the same for the last 15 years of study, the highest percentage of change corresponded to the period between 1993-2004, with a fall of -5.89%; for stomach cancer, the highest percentage of change occurred between 1975-1981, with a fall of -4.59%, followed by the period between 1981-2004 with -2.77%; for testicular cancer, the most important fall (-3.12%) corresponded to the period between 1987-2004. A slight fall was found in lung cancer and prostate cancer. In previous periods, both underwent important rises (Table 2).

Table 1 - Cancer mortality in Spain, 1975-2004

Site	Men			Women
	–APC	95% CL		–APC	95% CL

All cancers	0.56	0.39,	0.72	-0.41	-0.51,	-0.33
Lip	-3.62	-4.23,	-3.02	-3.39	-4.60,	-2.15
Esophagus	-0.28	-0.48,	-0.28	-2.73	-3.08,	-2.39
Stomach	-2.99	-3.13,	-2.85	-3.67	-3.80,	-3.52
Colon	3.72	3.18,	4.26	1.79	1.17,	2.41
Rectum	0.50	0.30,	0.70	-0.80	-0.10,	-0.70
Liver	-0.52	-0.64,	-0.41	-3.77	-4.00,	-3.52
Pancreas	2.21	1.95,	2.47	2.25	2.03,	2.50
Larynx	0.50	0.30,	0.71	-0.87	-1.04,	-0.77
Lung	1.18	1.47,	2.18	0.97	0.50,	1.37
Melanoma	5.64	4.70,	6.23	4.87	4.14,	5.60
Prostate	0.36	0.10,	0.60	-	-
Testicles	-2.45	-3.16,	-1.74	-	-
Urinary bladder	0.97	0.78,	1.17	0.32	0.01,	0.63
Kidney	2.65	2.30,	3.00	1.41	1.08,	1.73
Breast	-	-		0.66	0.23,	1.09
Ovary	-	-		3.69	3.22,	4.16
Uterus (body)				-2.04	-4.90,	0.98
Thyroid	1.13	0.39,	1.88	-0.10	-0.52,	0.30

APC, annual percent change. Per year, in all periods.

Table 2 - Several periods between 1975-2004 in cancer mortality in men in Spain

Site	Years	APC	95% CL

All cancers	1975-1995	1.03	0.94,	1.13
	1995-2004	-0.96	-1.27,	-0.65
Lip	1975-1993	-2.50	-3.59,	-1.39
	1993-2004	-5.89	-8.09,	-3.63
	1989-2004	-5.66	-7.11,	-4.19
	1975-1984	-5.14	-7.89,	-2.30
Esophagus	1975-1980	2.52	-3.40,	-1.58
	1980-1999	-0.76	-0.89,	-0.62
	1999-2004	-2.70	-3.63,	-1.76
Stomach	1975-1981	-4.59	-5.75,	-3.42
	1981-2004	-2.77	-2.97,	-2.61
Colon	1975-1981	-3.61	-6.13,	-0.62
	1981-1993	6.69	5.95,	8.02
	1993-2004	1.24	0.19,	2.49
Rectum	1988-2004	0.95	0.42,	1.41
	1975-1983	1.15	0.02,	2.38
	1986-2002	1.27	0.88,	1.67
Liver	1975-2002	-0.46	-0.58,	-0.33
	1975-1987	-0.68	-1.04,	-0.32
	1987-2002	-0.29	-0.58,	-0.09
Pancreas	1975-1985	4.21	3.56,	4.86
	1975-1985	4.16	3.48,	4.89
	1985-2002	1.51	1.19,	1.88
	1993-2004	-5.89	-8.09,	-3.63
	1989-2004	-5.66	-7.11,	-4.19
Melanoma	1975-1990	8.57	7.74,	9.90
	1990-2004	1.58	0.72,	3.00
Larynx	1975-1983	1.15	0.02,	2.39
	1983-1986	-3.06	-12.60,	7.51
	1986-2004	1.04	0.70,	1.38
Lung	1975-1991	3.55	3.13,	3.59
	1988-1994	1.58	0.31,	2.56
	1994-2004	-0.47	-0.82,	-0.05
Prostate	1975-1998	0.89	0.74,	1.04
	1998-2004	-3.45	-4.56,	-2.33
Testicles	1975-1995	-2.20	-3.53,	-0.90
	1987-2004	-3.12	-4.81,	-1.39
Kidney	1975-1996	3.49	3.17,	3.82
Urinary bladder	1975-1993	1.62	1.33,	1.96
	1980-1992	1.90	1.40,	2.42

APC, annual percent change per year. Only significant joinpoints were retained for each site.

In women, the following decreases in incidence were observed, per year: for lip cancer, -4.17% between 1975-1994; for stomach cancer, -5.84% between 1975-1980 and -3.45% between 1980-2004; for colon cancer, -6.22% between 1975-1982, and the following years the incidence increased significantly. Rectal cancer decreased throughout the research period, but the most noticeable fall (-1.28%) was between 1996-2004. Liver cancer decreased as well throughout the research period, but mainly between 1975-1987 with a decrease of -5.05%. Laryngeal cancer incidence also dropped during the research period. For lung cancer, of note was a slight fall between 1975-1992, followed by a period of significant increase in incidence. There was a small drop of -0.67% in the incidence of bladder cancer between 1986-2004.

One encouraging result was the 2.46% annual decline in breast cancer between 1993-2004 after having increased by 2.22% per year between 1975-1993. A surprising result was the decrease in uterine cancer between 1975-1981 (-36.7%), followed by a rapid 3.96% annual increase in the years between 1981 and 2004 (Table 3).

Table 3 - Several periods between 1975-2004 in cancer mortality in women in Spain

Site	Years	APC	95% CL

All cancers	1975-1981	-1.05	-1.59,	-0.50
	1981-1994	0.01	-0.18,	0.19
	1994-2004	-1.06	-1.31,	-0.81
Lip	1975-2000	-3.03	-4.65,	-1.93
	1975-1994	-4.17	-6.50,	-1.79
Stomach	1975-1980	-5.84	-7.24,	-4.41
	1980-2004	-3.45	-3.59,	-3.31
Colon	1975-1982	-6.22	-9.03,	-3.33
	1982-1988	8.77	3.31,	14.30
	1988-2004	0.81	0.07,	1.82
Rectum	1980-2004	-0.90	-1.17,	-0.68
	1980-1993	-1.15	-1.81,	-0.49
	1996-2004	-1.28	-2.33,	-0.21
Liver	1975-1987	-5.04	-5.51,	-4.53
	1987-2004	-3,02	-3.31,	-2.69
Pancreas	1975-1987	3.65	3.04,	4.26
	1987-2004	1.42	1.06,	1.77
Larynx	1975-1990	-0.73	-1.14,	-1.32
	1990-1993	-1.15	-1.81,	-0.49
	1996-2004	-1.28	-2.33,	-0.21
Lung	1975-1992	-0.66	-0.86,	-0.20
	1992-2004	2.28	2.05,	4.12
	1999-2004	5.23	3.16,	7.34
Melanoma	1975-1984	6.77	4.14,	5.60
	1984-1994	-0.43	4.11,	8.54
Urinary bladder	1975-1989	1.37	0.54,	2.20
	1987-2004	-0.67	-1.23,	-0.10
	1986-2004	-0.59	-1.01,	-0.17
Kidney	1975-1999	1.76	1.35,	2.16
Breast	1975-1993	2.22	1.99,	2.44
	1993-2004	-2.46	-2.90,	-2.07
Uterus (body)	1975-1981	-36.74	-46.6,	-24.9
	1981-2004	3.96	1.65,	6.32
Cervix	1975-1991	4.15	0.29,	8.16
Ovary	1975-1991	5.28	4.77,	-5.79
	1991-2001	1.15	0.26,	-1.58

APC, annual percent change per year. Only significant joinpoints were retained for each site.

Discussion

The overall cancer mortality rate in Spain in 2004 was 156.2 per 100,000 for men and 70.8 per 100,000 for women, representing about 33% and 27% of all deaths annually in Spain for men and women, respectively. The relative cancer mortality rate in Spain can be compared with that of Europe for 2002⁴. In 2002, overall cancer mortality in Spain compared favorably with the average for Europe: 166.0 vs 166.5 for men and 70.8 vs 95.2 per 100,000 for women in Spain and Europe, respectively. Although cancer mortality is Spain is in the middle range for European countries, it nevertheless takes a large toll in terms of years of life lost due to premature mortality and disability⁵. Cancer is the leading cause of death in Spain for men and women between the ages of 40 and 79. The greatest burden of cancer disease in Spain in terms of premature mortality and disability is due to lung, colorectal, breast, stomach and prostate cancer. Cancer of the lung, colon, prostate, and bladder are the leading causes of mortality in men primarily due to historically high smoking rates in Spanish men. Cancer mortality of the liver, kidney, stomach and brain are also high in men. For Spanish women, cancers of the breast, lung, colon, and stomach are the leading causes of mortality. Although in Spain women started smoking later than men, the rates reached high levels, and it is likely that smoking-related cancers will continue to increase in Spanish women in the near future.

Spain has made considerable progress in recent years in the battle against cancer mortality, primarily due to earlier diagnosis and more effective treatments. Since 1995, cancer mortality in Spain has decreased at a rate of about 1% per year in both men and women (Tables 1 and 2).

Lung cancer is the leading cause of cancer mortality in Spanish men and the third leading cause of cancer mortality in women. In contrast to the EU where lung cancer rates have declined by 1.9% per year in men^6,7 but have increased by 1.7% in women^8,9, lung cancer rates in Spain have not declined. Over the period 1975 to 2004, Spanish lung cancer mortality rates increased at an annual rate of 1.18% in men and 0.98% in women. Male lung cancer mortality in Spain appears to have peaked in 1994 and declined by about 5% by 2004. However, the lung cancer mortality rate in Spanish women is still rising.

Despite the persistent rise in female lung cancer in the EU, recent trends in cancer mortality in the EU are encouraging and indicate that an overall 11% reduction in total EU cancer mortality from 2000 to 2015 may be realistic. This is something that has not yet happened in Spain, where there has been a significant increase (46%) in lung cancer mortality in women under the age of 65 in recent years, for example in Navarre, Spain¹⁰. Reflecting this trend, lung cancer mortality rates in women for the whole of Spain increased at an annual rate of 4.64% between the years 1999 to 2004 (Table 3). In some European countries, lung cancer mortality in females has started to level off, whereas in Spain it is still rising. Lung cancer mortality in women has increased by 62% in the past 15 years and 30% in the past 5 years. In Spain, as in other countries, lung cancer is the second most common cause of cancer death in women after breast cancer (breast mortality is 13.3 per 100,000, whereas lung cancer mortality in women in Spain is 5.8 per 100,000.) The Spanish female lung cancer mortality rate is still below the average value of 11.4 per 100,000 for Europe in 2002, indicating a potential for continued growth.

Colorectal cancer remains a major cause of cancer mortality in Spain. Between the ages of 40 and 79, it is the second more frequent cause of cancer mortality in Spanish men and women (lung cancer is the first for men and breast cancer is the first for women). Colorectal cancer in Spain accounts for 11% of cancer mortality in men and 15% in women. This is comparable to Europe, where colorectal cancers are the second most diagnosed form of cancer, accounting for 13% of total cancer incidence, and also rank second in mortality, accounting for 12% of cancer mortality ¹¹. Colon cancer mortality has increased steadily in Spanish men from 1981 to the present, increasing at an annual rate of 6.7% from 1981 to 1993 and 1.3% for 1993 to 2004 (Table 2). Spanish women have experienced a similar rise, increasing at an annual rate of 8.6% from 1982 to 1988 and 0.81% from 1988 to 2004 (Table 3). As in many other European countries, colorectal cancer mortality rates in Spanish women are about 60% those of men, a difference that may be due to the fact that estrogens appear to be preventive of colon cancer. In many European countries, colon cancer mortality has been decreasing since about 1990. However, since these countries started at a higher colorectal cancer mortality rate than in Spain, colorectal cancer mortality in Spain is currently at about the same level as in Austria, Belgium, France, Italy, and Germany. The US National Cancer Institute estimates that 12% of US colorectal cancer deaths, where smoking rates are about half those in Spain, can be attributed to cigarette smoking ¹². Thus high smoking rates in Spain may be a contributing factor in Spanish colorectal cancer mortality. More attention needs to be given to early screening and prevention opportunities, since virtually all colon and rectal cancers can be prevented or cured by early intervention.

Breast cancer is the major cause of cancer mortality in women in most countries. Spain is no exception. Despite increasing attention to breast cancer early detection, breast cancer remains the leading cause of cancer mortality in Spanish women, although there has been a significant decline in mortality in recent years. Breast cancer accounts for 32% of cancer-related deaths in women in the EU and 33% in Spain (our estimate). From 1975 to 1993, breast cancer mortality increased at an annual rate of 2.22% and then decreased at a rate of 2.46% per year until 2004. The recent decline in breast cancer mortality can be attributed to early detection and increased effectiveness of cancer treatment programs. Despite the decline, breast cancer still represents about 24% of the burden of cancer mortality and morbidly in Spanish women. Breast cancer mortality is projected to remain high or increase from 2004 to 2016 in women over 50 due to aging of the population, and thus early detection needs to remain a focus despite recent declines.

Prostate cancer is the second most common cancer in Spanish men and accounts for about 29.4% of cancer mortality in men. Although there has been a huge rise in prostate cancer incidence over the last 20 years, this has not been reflected in mortality rates. Prostate cancer mortality in Spain increased at an annual rate of 0.9% between 1975 and 1998 and then decreased by 3.5% per year until the present. The recent decrease is primarily due to early detection since once prostate cancer has metastasized, it is almost always fatal. Prostate cancer incidence and mortality in Spain are about half those of other European countries such as Austria, Belgium, France, and Germany ¹³. Despite this, prostate cancer is the third leading cause of cancer mortality in men in both the EU and in Spain.

Over the past 30 years, mortality from cutaneous melanoma in Spain has increased by 5.6% in men and 4.9% in women (Table 1). Since 1999, the mortality rate appears to have leveled off and may be falling. Melanoma mortality appears to be decreasing also in other European countries. Age-standardized mortality for cutaneous melanoma in Germany decreased from 1.5 to 0.8 per 100,000 in males and from 2.6 to 0.8 per 100,000 in females, with a significant downward trend for the female population (P <0.001)^14,15. Mortality rates in Australia decreased in this period from 3.5 to 2.6 for males and slightly increased for females from 1.2 to 1.6 per 100,000 inhabitants¹⁶. Nevertheless, care must still be taken to continue with primary and secondary prevention, which influences mortality rates.

In summary, joinpoint analysis demonstrated favorable patterns in cancer mortality in recent years in Spain in both sexes. Cancer mortality has decreased significantly over the period 1975 to 2004. Tobacco-related cancers are the major contributor to cancer mortality in Spain, and despite the fact that smoking is the most significant modifiable risk factor for cancer, Spain continues to have one of the highest smoking rates in Europe. In recent years, tobacco-related cancers appear to have peaked in Spanish men, following a pattern of the rest of Europe. However, smoking continues to take a mortality toll in both Spanish men and women.

References

1. López-Abente G, Pollán M, Aragonés N, Pérez B, Hernández V, Lope V, Suarez B, Cardaba M: The situation of cancer in Spain Madrid, 2005. Available at http://www.isciii.es/htdocs/pdf/cancer-msc.pdf. (accessed December 3, 2009).

2. Esteve J, Benhamou E, Raymond L: Statistical methods in cancer research. Vol. IV. Descriptive epidemiology. IARC Scientific Publications nº 128. Lyon: IARC Press, p 170-211, 1994.

3. Kim H-J, Fay MP, Feuer EJ, Midthune DN: Permutation tests for joinpoint regression with applications to cancer rates. Stat Med, 19: 335-351, 2000.

4. Levi F, Lucchini F, Negri E, La Vecchia C: Continuing declines in cancer mortality in the European Union. Ann Oncol, 18: 593-595, 2007.

5. Fernández de Larrea-Baz N, Alvarez-Martín E, Morant-Ginestar C, Gènova-Maleras R, Gil A, Pérez-Gómez B, López-Abente G: Burden of disease due to cancer in Spain. BMC Public Health, 9: 42, 2009.

6. Shibuya K, Inoue M, Lopez AD: Statistical modeling and projections of lung cancer mortality in 4 industrialized countries. Int J Cancer, 117: 476-485, 2005.

7. Molinié F, Velten M, Remontet L, Bercelli P, Réseau Francim: The progression of lung cancer incidence in France (1978-2000). Rev Mal Respir, 23: 127-134, 2006.

8. Bosetti C, Garavello W, Levi F, Lucchini F, Negri E, La Vecchia C: Lung cancer mortality in European women. Ann Oncol, 16: 1597-1564, 2005.

9. Eilstein D, Uhry Z, Cherie-Challine L, Isnard H: Lung cancer mortality among women in France. Trend analysis and projection between 1975 and 2014, with a bayesian age-cohort model. Rev Epidemiol Sante Publique, 53: 167-181, 2005.

10. Moreno-Iribas C, Floristan Y, Egues N: Recent trends of the main causes of death in Navarre. 1995-2004. Ann Sist Sanit Navar, 29: 339-414, 2006.

11. Fernandez E, La Vecchia C, Gonzalez JR, Lucchini F, Negri E, Levi F: Converging patterns of colorectal cancer mortality in Europe. Eur J Cancer, 41: 430-437, 2005.

12. Chao A, Thun MJ, Jacobs EJ, Henley SJ, Rodriguez C, Calle EE: Cigarette smoking and colorectal cancer mortality in the cancer prevention study II. J Natl Cancer Inst, 92: 1888-1896, 2000.

13. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol, 3: 581-592, 2007.

14. Lasithiotakis KG, Leiter U, Gorkievicz R, Eigentler T, Breuninger H, Metzler G, Strobel W, Garbe C: The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003. Cancer, 107: 1331-1339, 2006.

15. Garbe C, Orfanos CE: Epidemiology of malignant melanoma in central Europe: risk factors and prognostic predictors. Results of the Central Malignant Melanoma Registry of the German Dermatological Society. Pigment Cell Res, Suppl 2: 285-294, 1992.

16. Coory M, Baade P, Aitken J, Smithers M, McLeod GR, Ring I: Trends for in situ and invasive melanoma in Queensland, Australia, 1982-2002. Cancer Causes Control, 17: 21-27, 2006.

111In-pentetreotide
125I seeds
2-indolinone
24-hour dietary recall
3D conformal radiation th
3D conformal radiotherapy
3D treatment planning
4-hydroxynonenal
5-ALA
5-fluorouracil
5-fluorouracil bolus
5-fluorouracil/leucovorin
5-HT3 antagonists
5Fluorouracil
5q deletion
99mTc-MDP bone scan
A/J mice
Abdominal aorta occlusion
Abdominal CT
Abdominal wall
Abdominopelvic anatomic s
Abdominopelvic regions
aberrant breast tissue
Abrikossoff’s tumor
Accelerated radiotherapy
acceleration
accessory breast
accompanying persons
accreditation
Acetyl-L-carnitine
Acquired thrombophilia
Active Breathing Coordina
Active iodide transport
Acupuncture
acute abdomen
Acute leukemia
acute liver failure
Acute myeloid leukemia
Acute toxicity
Adaptation
adaptive radiation therap
Adenocarcinoma
adenoid cystic carcinoma
Adenoma
Adenomyoepithelioma
adenosquamous carcinoma
adenoviral vector
adiposis dolorosa
adjuvant
Adjuvant chemotherapy
Adjuvant radiotherapy
Adjuvant therapy
adjuvant trastuzumab
Adjuvant treatment
Administrative data
adolescent
adrenal and sigmoid colon
adrenal cancer
Adrenal gland
adrenal gland metastases
adrenal incidentaloma
adrenal insufficiency
adrenal magnetic resonanc
adrenal malignancy
adrenal metastases
Adrenalectomy
Adrenomedullin
adult smoking
adult soft tissue sarcoma
adult-type granulosa cell
Adults
advanced
advanced breast cancer
Advanced cancer
Advanced cancer patients
advanced cervical cancer
Advanced colorectal cance
advanced colorectal neopl
advanced gastrointestinal
advanced squamous-cell or
adverse cutaneous effects
adverse effect
adverse event
age
Age distribution
age-period-cohort model
aged patients
aggressive non-Hodgkin%u2
AIDS
Air contrast barium enema
alcohol
Alexithymia
ALK expression
All cancers
allogeneic stem cell tran
allogenic transplantation
alopecia
alpha fetoprotein
altered fractionation
Alternating chemo-radioth
alternative medicine
amifostine
Amitriptyline
Ampulla of Vater
Ampullary neoplasm
Amputation
Amsterdam criteria
Anal cancer
anal fistula
anal neoplasms
Analgesics
anaplastic astrocytoma
Anaplastic gliomas
Anaplastic thyroid cancer
Anaplastic thyroid carcin
Androgen ablation
Androgen insensitivity sy
Androgen-independent pros
anemia
Angiocentrism
Angiofollicular lymph nod
Angiogenesis
Angiogenesis c-erbB-2
Angioimmunoblastic lympha
Angiomyolipoma
angiosarcoma
anorectal function
Anorexia
antagonist
anthracycline
anthracycline therapy
anti-Hu
Anti-smoking legislation
Anti-TPO antibodies
antiangiogenic therapy
antidepressant drugs
Antiemetic prescriptions
antiemetics
Antiestrogens
antineoplastic agents
Antineoplastic drugs
antioxidants
antiproliferative action
Antiretroviral therapy
antisense oligonucleotide
antismoking center
antithrombotic prophylaxi
antitumor agents
Antitumor immunity
anxiety levels
APC gene
apheresis
apolipoproteins
Apoptosis
appendiceal carcinoid tum
appendiceal mucinous neop
appendix
appendix mucinous neoplas
applicator position varia
appropriateness
apudomas
Argentina
aromatase inhibitors
array CGH
Arsenic trioxide
arsenic trioxide (As2O3)
Arterial hepatic infusion
artificial neural network
Asbestos
Asbestos exposure
Ascites
Ascites and omental disea
ASCUS
Askin tumor
assessment
astroblastoma
astrocytoma
astrocytomas
athymic mice
ATP-binding cassette subf
Atrial fibrillation
Atrial myxoma
attenuated familial adeno
attenuated Salmonella typ
atypical carcinoid
atypical lobular hyperpla
Atypical lymphocyte proli
atypical multiple scleros
Auditory
autograft
Autoimmune thyroid disord
Autologous and allogeneic
Autologous bone marrow tr
Autologous peripheral blo
Autologous stem cell resc
autonomic neuropathy
Autopsy
axillary dissection
axillary lymph node invol
Axillary lymph node metas
axillary lymph nodes
Axillary metastases
axillary radiotherapy
b-catenin
B-cell
b-cell lymphocytic leukem
B-cell NHL
BAG-1
Barrett's ablation
basal
Basal cell carcinoma
basal-like carcinomas
Basaloid squamous cell ca
Bax
Bayesian analysis
Bcl-2
BCL2
BCR-ABL
Bellini carcinoma
benchmarking issue
Benign breast disease
benign breast diseases
benign multicystic perito
Benzene
beta-2 microglobulin
beta-catenin
beta2-microglobulin
bevacizumab
beyond progression
BH3 domain
bilateral breast cancer
bile duct carcinoma
biliary
biliary obstruction
Bio-immunotherapy
biobank network
biochemical failure
biological resonance
Biomarker
Biomarkers
Biopsy
Biotherapy
Biphasic mesothelioma
Biphasic mixed tumors
Bisphosphonate
Bisphosphonates
Bladder
Bladder cancer
bladder carcinoma
Bladder function
bladder neoplasms
Bleomycin
Blood group antigens
Blue dye
BNIP3
body image
Body weight
bone
bone marrow
bone marrow aspirate
Bone metastases
Bone metastasis
bone tumor
bortezomib
Bowel obstruction
Brachytherapy
Brain
brain lesion
Brain metastases
Brain metastasis
brain tumor
Brain tumors
BRCA mutation
BRCA1
BRCA1 and BRCA2 genes
BRCA1/2
Breast
Breast cancer
Breast cancer diagnosis
Breast cancer phenotype
breast cancer recurrence
Breast cancer risk
Breast cancer screening
breast cancer subtype
Breast carcinoma
Breast edema
breast lesion
breast lump
Breast magnetic resonance
breast metastasis
breast neoplasm
Breast neoplasms
breast pain
Breast reconstruction
breast sarcoma
breast tumor
Breast vasculitis
Breast-conserving surgery
Breslow thickness
bronchial lavage fluid
Bronchiolitis obliterans
bronchopulmonary carcinoi
bronchoscopy
bronchoscopy specimen
C-erbB-2
c-ErbB2
Cachexia
Cadore
Calcitonin
Calibration
californium-252 neutron
Camurati-Engelmann diseas
Cancer
cancer antigen 125
cancer antisense therapy
cancer bleeding control
Cancer care facilities
cancer centre
cancer chemotherapy
cancer complication
cancer control
cancer control-planning
cancer cytogenetics
cancer diagnosis
cancer in spouses
Cancer incidence
cancer metastasis
Cancer mortality
Cancer pain
Cancer pain treatment
cancer prevalence,
cancer prevention
Cancer proteomics
Cancer registries
Cancer registry
cancer research
cancer research infrastru
cancer survival
Cancer therapy
cannabinoid receptor-1 ge
Capecitabine
capecitabine monotherapy
Capillary leak syndrome
carbon ion radiotherapy
carbon nanotubes
Carboplatin
Carcinoids
Carcinoma
Carcinoma erysipelatoides
Carcinomatosis
Carcinosarcoma
cardiac angiosarcoma
Cardiac dysfunction
Cardiac metastases
cardiac sarcoma
cardiac toxicity
cardiopulmonary bypass
Cardiotoxicity
carotid body tumor
carotid femoral and aorti
Case report
case-control studies
Case-control study
caspase-6
caspase-9
Castleman's disease
cathepsin
Cathepsin D
Catheters
caveolae
Cavernous hemangioma
cavernous liver angioma
CCEA
CCNU
CD-138
CD10
CD105 (endoglin)
CD117
CD34
CD4+
CD40
cd40 ligand
CD40L
CD44
CD8+
CD8+ T cell
CD99
CDX-2
Celiac disease
Celiac plexus block
cell cycle
cell cycle proteins
cell death
cell invasion
cell migration
cell proliferation
cell toxicity
Cell types related marker
cell-specific magnetic re
cellular therapy
Central nervous system pr
central venous devices
Cerebellar metastasis
cerebral meningioma
Cervical cancer
Cervical cancer epidemiol
Cervical carcinoma
cervical chordoma
Cervical dysplasia
Cervical intraepithelial
cervical intraepithelial
cervical node metastasis
cervical plexus
cervical squamous cell ca
Cervix
cetuximab
Changes in molecular biol
Chemoprevention
Chemoradiation
Chemoradiotherapy
Chemotherapy
Chemotherapy at the end o
chemotherapy toxicity
chemotherapy-induced
chemotherapy-induced naus
Chemotherapy-induced peri
Chest reconstruction
Childhood
Childhood cancer
children
China
cholesterol
Chondrosarcoma
Chordoma
Chorioallantoic membrane
Choroidal metastasis
Chromogranin A
chromogranin-A
Chromosomal aberration
chromosome 3
chronic leukemia
chronic myeloid leukemia
Chronomodulated infusion
Chronotherapy
chylous ascites
Cigarette smoking
CIN
Ciplatin
cirrhosis
Cisplatin
Cisplatin-resistant metas
CK 5/6
classic Kaposi’s sarcom
Classification
clear cell renal carcinom
Clinic-pathological aspec
Clinical and pathological
Clinical audit
Clinical features
Clinical indications
clinical indicators
Clinical practice
Clinical stage
clinical stage I
Clinical staging
Clinical trial
Clinical trials
Clonality
Clozapine
CMF
CMF regimen
co-culture
CO2 laser
coagulation
Cohort studies
Cohort study
Cohort stuudies
collecting duct carcinoma
Colo-anal anastomosis
Colon
Colon adenocarcinoma
Colon cancer
Colon carcinoma
colon carcinoma metastasi
Colon metastases
Colonic adenocarcinoma
Colonoscopy
color Doppler sonogram
colorectal
Colorectal adenocarcinoma
Colorectal cancer
colorectal cancer liver m
Colorectal carcinoma
Colorectal neoplasms
colorectal screening
colorectal surgery
Colorectal tumor
Colorectal tumors
colposcopy
combined chemoradiotherap
Combined modality therapy
Combined modality treatme
Combined therapy
combined tumor
Combined-modality treatme
Comet assay
commissioning
common diagnostic pitfall
communication
communication of bad news
comorbidity
comparative genomic hybri
Comparative studies
Competitive PCR
complementary medicine
Complete response
Complications
composite hemangioendothe
comprehensive geriatric a
comprehensiveness
Computed tomography
computed tomography (CT)
computer-assisted reading
Computerized tomography
concomitant
concomitant boost
concomitant radiochemothe
CONCORD
Concurrent boost radiothe
Concurrent chemo-radiothe
concurrent chemoradiother
Conflict of interest
conformal boost
conformal external beam r
Conformal radiotherapy
congenital breast malform
Conization
conservative management
Conservative radiotherapy
Conservative surgery
Conservative treatment
consolidation chemotherap
continuous 5-fluoruracil
Continuous infusion
Contrast enhancement
coordination
Cordoba
Core biopsy
core needle biopsy
Coronary ostial stenosis
Correct sun exposure
cosmesis
Cosmetic results
cost
cost-effectiveness
cotyledonoid dissecting l
cox-2
coxofemoral arthrodesis
CpG island methylation
Cranial metastases
cranial trauma
craniospinal irradiation
cribriform carcinoma of t
cricoid cartilage
cricoid tumor
Croatia
cross-talk
Crude rates
Cryoglobulinemia
Crystal-storing histiocyt
CT
cultural diversity
Curettage mastectomy
Cushing's syndrome
Cutaneous melanoma
cutaneous tumors
cyberKnife
cyclooxygenase-2
cyclophosphamide
cyst
cystadenocarcinoma
cystatin
cystectomy
Cystic components
cystic hygroma
cystic lymphangioma
Cystic mesothelioma
cystic neuroendocrine pan
Cystoprostatectomy
cytarabine
Cytogenetic analysis
Cytogenetic biomarkers
cytogenetics
Cytokine
Cytokines
cytology
Cytomegalovirus
Cytoreduction
Cytoreductive surgery
Cytotoxic granules
cytotoxic T lymphocytes
dacryocystitis
DAPI
DAPk
Daunorubicin
De novo
de novo colon cancer
dead children
Deep venous thrombosis
Delayed onset
delays in diagnosis
Delivery
Dendritic cells
Dendritic cells inflammat
dental factors
Depression
Dercum’s disease
dermatofibrosarcoma protu
Dermoid cyst
Dermoscopic diagnosis
Dermoscopy
Desmoid tumor
Desmoid tumors
desmoplastic small round
Desmoplastic small round-
Desmoplastic tumor
detergent resistant micro
dexrazoxane
DFMO
diabetes
diabetes insipidus
Diagnosis
diagnosis disclosure
diagnostic imaging
diagnostic laparotomy
diagnostic odds ratio
dialysis
Diet
Dietary questionnaire
differential diagnosis
Differentiated thyroid ca
Differentiated thyroid ca
Diffuse gastric cancer
diffuse large B-cell lymp
Dihydrotestosterone
Diplopia
Discomfort
disease management
disease progression
disease-free period
disease-oriented bioban
disseminated intravascula
distance education
Distant metastases
DNA
DNA binding
DNA damage
DNA methylation
DNA microarrays
DNA ploidy
DNA repair
DNA sequencing
docetaxel
Dose calculation algorith
Dose fractionation
dose intensification
dose-dense chemotherapy
dose-finding study
dose-intense
Dose-intensity
Dose-volume histograms
Dosimetric calibration
dosimetric variation
Down syndrome
Down-staging
downdose
Doxorubicin
Doxycycline
DRAK1
Drinking habits
drug delivery
Ductal adenocarcinoma
Ductal carcinoma in situ
Ductopenia
duodenal
Duodenal neoplasm
Duodenocephalo-pancreasec
duodenum
Dural involvement
duration of treatment
DVL1
dynamic micro-multileaf c
dysphonia
dyspnea
Dysproteinemia
E-cad
E-cadherin
E-selectin
Early breast cancer
Early cancer
Early diagnosis
early gallbladder carcino
Early glottic carcinoma
Early polypoid colorectal
early rectal cancer
early stage
Early stage lung cancer
early technology assessme
eccrine mucinous adenocar
Ecological monitoring
Ectopic
ectopic breast
Ectopic pregnancy
Edema
Educational level
Educational message
EGFR
eLAV-like protein
Elderly
elderly cancer patients
elderly patient
Elderly patients
elective nodal irradiatio
electrocardiogram
electrochemotherapy
electromagnetism (EM)
electromyography
electronic chart
electroporation
Embolization
Emergency surgery
en bloc resection
Encephalopathy
end of life
End-of-life care
end-stage renal impairmen
endocrine system
Endodermal sinus tumor
endoG expression
endogenous porphyrins
Endometrial cancer
Endometrial carcinoma
endometrial tumor
Endometrium
Endoscopic ablation
endoscopic removal
endoscopy
Energy expediture
Engineered tumor cells
Enhancement
Enoxaparin
enteric nervous system
enterocutaneous fistula
Environmental exposure
Environmental pollution
Environmental tobacco smo
EORTC questionnaire
ependymomas
EPIC
epidemiologic methods
Epidemiology
epidermal growth factor
epidermal growth factor r
Epigenetic alterations
Epigenetics
Epirubicin
epithelioid
Epithelioid sarcoma
Epo
Epoetin alfa
Epstein-Barr virus
Epstein-Barr virus (EBV)
ER
era
erB-2
erlotinib
errors in radiation deliv
erythroleukoplakia
Erythropoietin
Esophageal adenocarcinoma
Esophageal cancer
Esophagogastroscopy
Esophagus
esophageal cancer
esthesioneuroblastoma
estrogen receptor
estrogen-progesterone rec
Ethics
Ethics committees
Ethmoid cancer
Ethnic distribution
European Union
euthanasia
event tree model
evidence-based medicine
Ewing sarcoma
Ewing's sarcoma
Ewing’s sarcoma
Ewing’s sarcoma family
exemestane
Exercise testing
exonic splicing enhancers
exosomes
experimental
extended cholecystectomy
External beam radiotherap
Extra-abdominal metastasi
Extracapsular extension
Extracellular matrix prot
Extradonal non-Hodgkin's
Extragonadal germ cell tu
extramedullary plasmacyto
Extranodal lymphoma
extranodal MALT lymphoma
Extraosseous Ewing's sarc
extraosseous sarcoma
Extrapulmonary small cell
Extravasation
eyelid
ezrin
facial nerve
false positive
Familial adenomatous poly
Familial polyposis
families
family
Fas/FasL
fatigue
FDG-PET
feasibility
febrile neutropenia
Female
fetal dose
FHIT gene
Fibroma
fibromatosis
fibronectin
fibrosis
filgrastim
Finasteride
fine-needle aspiration cy
FISH
Fistula
fixed-dose-rate infusion
FLIPI
Floxuridine
fluorescence
Fluoropyrimidine-pretreat
Fluorouracil
FMF
focal adhesion kinase
Focal nodular hyperplasia
folate
FOLFIRI
folfox
FOLFOX IV/LV5FU2 chemothe
FOLFOX regimen
folinic acid
Follicular carcinoma
Follicular lymphoma
follicular thyroid cancer
follow-up
Food
Forearm
foregut neuroendocrine ca
Four or more positive axi
Fractionated stereotactic
fractionation
fraud
fullerenes
fulminant liver failure
G-CSF
galectin-1
galectin-3
Gallbladder
Gallbladder carcinoma
Gamma probe
Gamma-glutamyltransferase
gastrectomy
Gastric cancer
Gastric carcinoma
Gastric melanoma
gastric myoepithelial ham
gastrointestinal carcinoi
gastrointestinal interven
Gastrointestinal lymphoma
Gastrointestinal neoplasm
Gastrointestinal stromal
Gastrointestinal stromal
gastrointestinal stromal
gastrointestinal stromal
Gemcitabine
Gender differences
Gene expression
gene expression profile
gene polymorphism
gene therapy
General practitioners
Genetic research
genetic susceptibility
Genetic testing
Genetic tests
Genomic instability
genomics
genomics
GEP neuroendocrine tumors
germ cell tumor
germ cell tumors
Germline mutations
gestational trophoblastic
giant basal cell carcinom
giant follicles
giant keratoacanthoma
Giant mixed retroperitone
Giemsa
GIST
glioblastoma
Glioblastoma multiforme
Gliofibroma
Glioma
gliosarcomas
Glottic cancer
glucagon
glucose-6-phosphate dehyd
glutamine
glutathione S-transferase
glycoproteins
Gonadoblastoma
good clinical practice
Good's syndrome
GPI
granular cell tumor
granulocyte-colony stimul
granulocytic sarcoma
Granulomatous angiopannic
Granulomatous gastritis
Graves' disease
growth inhibitory peptide
growth rate
GSTP1
guidelines
Guillain-Barré syndrome
Gynecomastia
Gynecomastia and hormone
Gynecomastia and prostate
H. pylori
Hadron therapy
hairy cell leukemia
half-body irradiation
hamartoma
Hand-foot syndrome
Hashimoto’s thyroiditis
HBV/HCV infections
HCV
HDR brachytherapy
Head and neck
Head and neck cancer
Head and neck carcinoma
Head and neck malignancie
head and neck neoplasms
head and neck tumor
Head trauma
Health-related quality of
healthy donors
Heart
heart failure
heart transplantation
heat
heat shock protein 70
heavily pretreated
Hemangioendothelioma
Hemangiopericytoma
Hemangiosarcoma
Hematological malignancie
hematological malignancy
Hematopoietic stem cell t
hematuria
Hemodialysis
Hemoglobin levels
hemoperitoneum
hemophilia A
Hep-2 cells
Heparin
Hepatic adenosquamous car
Hepatic arterial infusion
Hepatic arterial infusion
Hepatic artery
hepatic tumor
Hepatitis B virus
hepatitis B virus (HBV)
Hepatitis B virus integra
Hepatitis C virus infecti
hepatoblastoma
Hepatocellular
Hepatocellular carcinoma
hepatocellular carcinoma
hepatocyte growth factor
HER-2
HER-2 receptor
HER-2/neu
HER2
HER2-positive metastatic
Herceptin
Hereditary breast cancer
hereditary non-polyposis
HEY1
high dose
High dose chemotherapy
high dose rate
high genetic risk
high-dose boost
High-dose chemotherapy
high-dose epirubicin
High-dose rate brachyther
high-grade glioma
High-grade squamous intra
high-risk medulloblastoma
Histogenesis
histological diagnosis
Histological score
HIV
hMLH1
hMLH1 hypermethylation
HNPCC
Hodgkin disease
Hodgkin's disease
Hodgkin's disease (HD)
Hodgkin’s disease
Home palliative care serv
homocysteine levels
Horizontal growth phase m
Hormone receptor status
Hormone refractory
hormone replacement thera
Hormone therapy
Hormone-refractory prosta
Hormonorefractory
Hormonotherapy
Hospital
Hospital-based population
HPV
Hrthle cell carcinoma
hTERT
hu-PBL/SCID chimera
huge hepatocellular carci
Human
human carboxylesterase-2
Human chorionic gonadotro
Human Epo receptor (EpoR)
Human G-CSF receptor
Human immunodeficiency vi
Human papilloma virus
Human papillomavirus
human sarcoma
Human tumor cell lines
hur
hydration
hydrocele
Hydrogen peroxide
hydronephrosis
Hypercoagulable state
Hypereosinophilic idiopat
Hyperfractionated radioth
Hyperfractionation
Hyperparathyroidism
Hypersensitivity reaction
Hypertermic tissue ablati
hyperthermia
Hypocalcemia
Hypofractionation
Hypoparathyroidism
hypopharyngeal cancer
hypothyroidism
ICCC-3
ICD-10
Id2 protein
Idiopathic thrombocytopen
IFN-a-2a
Ifosfamide
IgR
IHH
IL-12
IL-2
ileal carcinoid
ileal mucosa
image analysis
image fusion
Image probing
image-guided intensity-mo
Image-guided radiotherapy
imaging
imatinib
Imatinib mesylate
imiquimod
immune host response
Immunity
immunocompetent host
immunocytochemistry
Immunodeficiency
immunohistochemical analy
Immunohistochemical marke
Immunohistochemistry
Immunoradiometric assays
Immunoscintigraphy
Immunotherapy
impact factor
Implantable port
IMRT
in vivo imaging
in vivo small animal magn
inappropriate doses of ch
incentives
Incidence
incidence rates
Independent studies
induced lymphoma
induction chemotherapy
induction therapy
infant
infantile myofibromatosis
infection
Infections
infectious agents
infiltrating ductal carci
Inflammation
Inflammatory bowel diseas
Inflammatory breast carci
Inflammatory mechanism
Inflammatory metastatic c
inflammatory myofibroblas
inflammatory pseudotumor
Informed consent
infrastructures
infusion reaction
Infusional chemotherapy
infusional therapy
Inguinal canal
Inguinal hernia
Inoperable bowel obstruct
insular
Insular thyroid carcinoma
Insurance
integral dose
Integrated radiotherapeut
integration
integrin beta 3
intensity modulated radia
Intensity-modulated exter
Intensity-modulated radia
Intensity-modulated radia
intensity-modulated radio
Interaction
Interactive computer grap
Interferon
interferon beta
Interleukin-2
Interleukin-6
interleukins
Intermediate emetogenic c
internal mammary node met
international collaborati
international cooperation
International Prognostic
internet
Interobserver agreement
Interpectoral (Rotter's)
interstitial pneumonitis
interval cancer
interval cancers
interval censoring
Interventional radiology
intestinal permeability
intestinal pouch
intima-media thickness
Intra-arterial chemothera
intra-operative radiother
Intraabdominal tumor mass
Intracranial tumors
Intraductal carcinoma
Intrahepatic cholangiocar
Intrahepatic cholestasis
intramedullary metastases
intramedullary tumor
intraoperative pathologic
Intraoperative radiothera
intraosseous hemangioma
Intraperitoneal chemother
intraperitoneal chemoth
Intraperitoneal hyperther
intratumoral lymphocyte
Intravascular lymphomatos
Invasion
Invasive ductal carcinoma
invasiveness
Ionizing irradiation
IORT
Iran
Irinotecan
iris metastasis
iron oxide nanoparticle
isolated splenic metastas
isothiocyanates
Italian cancer burden
Italian cancer control
Italian EPIC population
Italian Sarcoma Group
Italy
jaw
jaws
jejunal intussusception
Job's syndrome
joinpoint analysis
Juvenile granulosa cell t
K-ras
k-ras codon 12 mutation
Kaposi's sarcoma
Kaposi’s sarcoma
keratin
Keratin/genetics
keratoacanthoma
Ki-67
Ki-67 antigen
Ki-ras gene
Ki67
Kidney
kidney transplantation
KIT
kit protein
Korea
Krukenberg tumor
Kyphoplasty
lab-on-chip
labelling
Lacrimal sac
Lactulose-mannitol test
Laminin
lamivudine
Laparoscopic cholecystect
laparoscopic splenectomy
Laparoscopic surgery
laparoscopy
Large breast
laryngeal cancer
laryngeal chondrosarcoma
Laryngeal neoplasm
larynx
Larynx carcinoma
late brain metastases
late complication
Late effects
late effects of cancer tr
late relapse
Late side effects
Late toxicity
latent membrane protein 1
Leading cancer sites
Leiomyosarcoma
leptomeningeal metastases
Leucovorin
Leydig cell tumor
Li-Fraumeni syndrome
life tables
Life-style
Life-style questionnaire
Limited stage
lipid-rich carcinoma
Liposarcoma
Liposomal doxorubicin
Liposomes
Liquid-based cytology
literature review
Liver
liver cancer
liver failure
Liver malignancies
Liver metastases
Liver metastasis
liver neoplasm
Liver resection
Liver transplantation
Liver tumors
lobectomy
Lobular carcinoma
lobular carcinoma in situ
lobular neoplasia
Local control
Local recurrence
local tumor recurrence
local-regional recurrence
localized carcinoma of th
localized gastrointestina
localized non-Hodgkin's l
Locally advanced
Locally advanced breast c
Locally advanced breast t
Locally advanced disease
locally advanced lung can
Locoregional chemotherapy
Locoregional radiotherapy
Lomustine
Long-surviving patient
long-term complications
long-term follow-up
Long-term outcome
Long-term remission
Long-term survival
Long-term-survivors
loss of heterozygosity
loss of heterozygosity (L
Loss of heterozygosity,
low dose intensity
low dose rate
lumpectomy
Lung
Lung adenocarcinoma
Lung cancer
lung cancer prognosis
Lung carcinoma
Lung metastases
lung metastasis
Lung neoplasm
Lung neoplasms
lung resection
lung toxicity
lymph node
lymph node diameter
Lymph node excision
Lymph node failure
Lymph node metastases
lymph node sampling
Lymph node status
Lymph node-negative breas
Lymph nodes
Lymphadenectomy
Lymphangioleiomyomatosis
lymphatic mapping
lymphocytes
lymphofollicular infiltra
Lymphoma
Lymphoscintigraphy
MAb CIBCgp185
macrophage
Magnetic resonance
Magnetic resonance imagin
maintenance chemotherapy
major surgery
Male breast cancer
Male breast carcinoma
Malignancy
malignant breast disease
malignant fibrous histioc
Malignant fibrous histioc
malignant giant cell tumo
malignant glioma
malignant gliomas
malignant infiltration of
Malignant melanoma
malignant mesenchymoma
malignant mixed mesoderma
Malignant pericardial tum
malignant peripheral nerv
Malignant pleural Mesothe
malignant thymoma
Malignant transformation
Malnutrition
MALT lymphoma
mammary phyllodes tumor
Mammography
mammography screening
Mandibular metastasis
Mandibular tumors
manifestation
mantle cell lymphoma
Margin involvement
mastalgia
mastectomy
matrix metalloproteinase-
matrix producing carcinom
Mature cystic teratoma
maxillary sinus
MCC
Mediastinal radiotherapy
mediastinal staging
Mediastinum
medical choice
Medical ethics
medical oncologist’s tr
medullary breast cancer
medullary carcinoma
Medullary thyroid cancer
Medullary thyroid cancer
Medullary thyroid cancer
Medullary thyroid carcino
Medullary thyroid carcino
Medullary thyroid carcino
Megestrol acetate
Melanin
melanocytoma
melanoma
Melanoma prevention
Membranous glomerulonephr
MEN 2 syndromes
MEN 2A
MEN 2B
meningeal carcinomatosis
Meningeal hemangiopericyt
Meningioma
Menopause
Menstrual cyles
menstrual induction
mental adaptation to canc
Merkel cell carcinoma
mesenchymal chondrosarcom
mesenchymal tumor
mesenteric cyst
Mesenteric fibromatosis
Mesenteric paraganglioma
Mesenteric thrombosis
mesentery
Mesothelioma
Meta-analysis
metacarpal bone
metachronous metastasis
metaiodobenzylguanidine s
Metaiodobenzylguanidine t
metallic implants
metalloproteinase
metallothioneins
Metanephrines
metaplastic carcinoma
metastasectomy
Metastases
Metastasis
metastasis of unknown ori
metastasis to stomach
Metastatic bone disease
Metastatic breast cancer
Metastatic cancer
metastatic cancers
Metastatic colorectal can
metastatic gastric cancer
metastatic liver disease
metastatic non-small cell
metastatic ovarian tumor
Metastatic prostate carci
Metastatic spinal cord co
metatarsal bones
methodological approaches
methylation
Methylene blue
metronomic therapy
MGMT
mice
microcalcification
Microcalcifications
Microenvironment
micropapillary
Microvascular density
Midline lymphoma
Minimal change disease
minors
Mismatch repair genes
mitogen-activated protein
mitomycin C.
mitomycin-C
Mitoses
mitotic catastrophe
Mitotic index
Mitoxantrone
Mixture models
MLH1
MMP
mobility
molecular diagnostics
Molecular follow-up
Molecular markers
monoclonal antibody
mononuclear cell migratio
Morbidity
morbidity-mortality
Mortality
Moschcowitz's disease
Motility
MRI
MSH2
MTA
MTHFR
mucinous adenocarcinoma
mucinous tumors
Mucosa-associated-lymphoi
mucosal damage
mucosuria
multi-drug resistance
multi-drug resistance pro
multicentric trial
multidisciplinary treatme
multiendocrine failure
multikinase inhibitor
multileaf collimator
Multimodality therapy
multimodality treatment
multiple bladder-prostate
multiple endocrine neopla
Multiple lymphangiomas
multiple malignancies
Multiple malignancy
Multiple myeloma
multiple primary cancers
multiple sclerosis
Multipurpose surveys
Multivariate analysis
Muscle cell proliferation
mutation
myasthenia
mycosis fungoides
myelodysplastic syndrome
myeloid markers
myocardial metastasis
myocardial perfusion defe
myocardial perfusion scin
myoepithelial cells
myoid
Na+-I- symporter
nanomedicine
nanoparticles
nanotechnology
nanomedicine
nanoparticles
nasal septum
Nasopharyngeal cancer
Nasopharyngeal carcinoma
nasopharyngeal neoplasm
Nasopharynx
National survival estimat
Natural killer cells
Neck
neck dissection
neck mass
neck metastases
Neck's tumors
necrosis
negative second-look lapa
neoadjuvant
neoadjuvant chemoradiatio
Neoadjuvant Chemotherapy
neoadjuvant radiotherapy
Neoadjuvant therapy
neoadjuvant,Taxotere
Neoplasm
Neoplasm circulating cell
neoplasm metastasis
Neoplasms
neopterin.
Neovascularization
nephrectomy
Nephrotic syndrome
nephrotoxicity
Nerve-sparing
Network
networks
neural tissue
neurilemmoma
Neuroanatomy
neuroblastoma
neuroendocrine carcinoma
Neuroendocrine differenti
Neuroendocrine tumor
Neuroendocrine tumors
neurofibromatosis 2
neurogliocytoma
Neurological state
Neuron-specific enolase
Neuropathic pain
neurosurgery
neurotoxicity
neutropenia
neutropenic enterocolitis
New bisphosphonates
new schedule
NF-ÛB
NF1
nipple-sparing mastectomy
NIS expression
NIS therapy
Nitric oxide
NK activity
NK cells
NK lymphoma
nm23
Nodal regions
nomograms
Non-functioning adrenocor
non-Hodgkin disease
Non-Hodgkin lymphoma
non-Hodgkin lymphomas
non-Hodgkin’s lymphoma
non-melanoma skin cancers
non-non-Hodgkin's lymphom
Non-palpable breast lesio
Non-palpable thyroid nodu
non-pegylated doxorubicin
Non-platinum chemotherapy
Non-profit clinical trial
non-seminoma
Non-smal cell lung cancer
Non-small cell lung cance
non-small cell type
non-small-cell lung cance
non-viral vectors
Nongestational choriocarc
nonlinear resonance inter
nonpigmented ciliary epit
nonseminomatous germ cell
norcholesterol scintigrap
Nosocomial infections
Nottingham prognostic
novel mutations
NSCLC
Nuclear medicine therapy
nucleic acid delivery
nutrient mixture
nutritional status
Obesity
obscure digestive bleedin
Occult blood
Occult primary
occult/obscure gastrointe
occupational exposure
octreoscan
Octreotide
Ocular
ocular adnexal lymphoma
odontogenic tumors
off-label
older population
oligonucleotides
omentum
Omentum.
Oncocytic neoplasm
oncogene
oncogenes
Oncogenomics
Oncology
Opioid consumption
opportunistic screening
optical biopsy of cancer
optical imaging
optical neuritis
Optimized screening
oral cancer
oral cavity
Oral mucositis
oral precancerous conditi
oral UFT (tegafur-uracil)
oral vinorelbine
orbit
Orbital involvement
Orbital metastasis
Orbital surgery
organisation of care
Orgotein
Oropharynx
Orthovoltage therapy
osteo-oncology
Osteoclastic activation
osteonecrosis
osteopetrosis
osteopontin
Osteosarcoma
osteosarcoma of the kidne
osteosarcomatous differen
outcome
outpatient regimen
Ovarian cancer
Ovarian carcinoma
ovarian endometriosis
ovarian malignancy
ovarian psammocarcinoma
ovarian teratoma
Ovarian tumor
Ovary
over-treatment
overall survival
Overdose
Overexpression
Oxaliplatin
oxidative phosphorylation
p105
p14
p16
p185HER2
p27Kip1
p53
p53 antibodies
p53 gene
p53 mutation
p53 protein
p57Kip2
p63
p73
Pacemaker
Paclitaxel
Paclitaxel-carboplatin
Paget’s disease
PAI-1
Pain mechanisms
painful lipomas
palliative care
palliative care in oncolo
Palliative chemotherapy
palliative radiation ther
palmar-plantar erythrodys
palonosetron
pancreas
Pancreatic cancer
pancreatic carcinoma.
pancreatic cyst
pancreatic ductal adenoca
pancreatic heterotopy of
pancreatic intraductal pa
Pancreatic metastases
pancreatic neoplasm
pancreatic neoplasms
Pancreatic resection
pancreaticoduodenectomy
panitumumab
Pap smear history
Pap smear screening
Pap smears
Papillary carcinoma
Papillary fibroelastoma
papillary thyroid carcino
Paraganglioma
paralytic ileus
parametric model
paranasal sinuses
Paraneoplastic nephrotic
Paraneoplastic neurologic
Paraneoplastic syndrome
Paraplegia
Paraspinal tumors
Parathyroid
parathyroid adenoma
Parathyroid carcinoma
Parathyroid hormone (PTH)
Parathyroidectomy
Parenteral nutrition
parotid carcinoma
parotid gland
parotid neoplasm
partial laryngectomy
pathology
Pathology related markers
Pathway
patient satisfaction
patient-physician relatio
patterns of care
Patterns of failure
paxillin
PCR
PDGF
PEComa
pediatric
pediatric oncology
pediatric tumors
pegfilgrastim
Pegylation
Pelvic CT
Penile metastases
perfusion
Periampullary stromal tum
perineal prostatectomy
Perioperative radiotherap
Peripheral blood progenit
peripheral blood stem cel
peripheral leukocytes
peritoneal carcinomatosis
Peritoneal mesothelioma
Peritonealcancer
Peritonectomy
Peritoneovenous shunt
Peritoneum
peritumoral hepatic tissu
perivascular epithelioid
Permanent prostate Brachy
PET
PET sensitivity
PET.
PET/CT
Pharmaceutical industries
pharmacoeconomics
Pharmacoeconomy
pharmacogenetics
Pharyngolaryngeal squamou
Phase I
Phase II study
Pheochromocytoma
Pheochromocytoma treatmen
Phosphoinositide 3-kinase
photo excitation
Photofrin
Photosensitizer
phyllodes tumor
Physical activity
Physicians
physiotherapy
Pituitary adenoma
pituitary gland
pituitary gland metastasi
placental site trophoblas
planning study
Plasma fatty acid
plasmacytoid
Plasmacytoma
Plastic ring
Plastic surgery
Platinum
pleomorphic adenoma
Pleura
Pleural neoplasms
pleural small cell carcin
Pleurocentesis
Ploidy
Pneumonectomy
point mutations
point-of-care
Pollution
poly(butyl cyanoacrylate)
poly(lactide-co-glycolic
Polyamines
polychemotherapy
polycystic liver disease
Polymerase chain reaction
polymorphism
polymorphous
polysomy
ponicidin
population surveillance
Population survey
Population surveys
population-based
Population-based study
population-based survey
Porphyrins
port site recurrence
Positron emission tomogra
positron-emission tomogra
Post-irradiation sarcoma
Post-radiation osteosarco
Post-remission treatment
Post-traumatic glioma
Post-traumatic meningioma
Post-treatment CIN
Postoperative chemoradiat
postoperative radiochemot
Postoperative radiotherap
Postoperative therapy
PP1 inhibitor
PR
Practice guidelines
pRb
pre-operative chemotherap
Predictive value
Prednisone
Pregnancy
Preoperative chemoradiati
preoperative diagnosis
preoperative immunotherap
preoperative radiochemoth
Preoperative radiotherapy
pretreatment tumor lysis
Prevalence
prevalence of use of comp
prevention
Prevention and control
Priapism
Primary
primary adenocarcinoma
primary bilateral adrenal
primary central nervous s
primary chemotherapy
primary cultures
primary duodenal adenocar
primary hepatic leiomyosa
primary hyperparathyroidi
primary lung tumors
primary osteosarcoma
primary pancreatic lympho
primary systemic therapy
Primitive neuroectodermal
proctocolectomy
progesterone receptor
Prognosis
Prognostic factor
Prognostic factors
Prognostic markers
prognostic parameter
Prognostic score
proliferating trichilemma
Proliferation
proliferation index
prone position
Prophylactic total thyroi
Prospective cohort study
Prospective longitudinal
Prospective study
prostaglandin-endoperoxid
Prostate
Prostate adenocarcinoma
prostate biopsy
Prostate cancer
Prostate carcinoma
prostate neoplasms
Prostate specific antigen
prostate-specific antigen
Prostatectomy
Prostatic ducts
Prostatic neoplasm
prostatic neoplasms
protection
Protein microarray
Protein S
Proteomics
Proteomics technologies
Proton beams
proton therapy
PSA test
Pseudomyxoma peritonei
Psoriasis
psychosexuality
psychosocial
Psychosocial adjustment
psychosocial support
PTCA
PTEN
Pulmonary
Pulmonary adenocarcinoma
Pulmonary blastoma
Pulmonary fibrosis
Pulmonary lymphoma
pulmonary non-Hodgkin’s
Pulmonary valve
Pylethrombosis
pyogenic liver abscess
Pyrene
quality assurance
quality indicators.
quality of care
Quality of life
quality score system
Quantification
quantitative real time po
questionnaire
questionnaires
Radiation
Radiation safety
Radiation therapy
Radiation-induced meningi
Radiation-induced tumors
Radiation-induced
Radical hysterectomy
Radical nephrectomy
radical surgery
radiochemotherapy
Radiofrequency ablation
Radiograph
Radioguided surgery
Radioiodine therapy
radiologic diagnosis
radiologically dense brea
radiometabolic therapy
Radionecrosis
Radionuclide therapy
radioprotection
radiosensitivity
Radiosensitizer
radiosensitizing
Radiosurgery
Radiotherapy
Radiotherapy fractionatio
radiotherapy treatment
Radiotherapy treatment pl
radiochemotherapy
Raloxifene
Ralstonia pickettii
Raltitrexed
ramosetron
Random sample
randomized controlled cli
Randomized controlled stu
Randomized controlled tri
randomized phase III tria
RARb
rare entity
rash
RASSF1A tumor suppressor
RCC
Re-irradiation
reactive lymphoid hyperpl
reactive oxygen species
Recall colitis
receptor
receptors
recognization
recombinant human growth
Recombinant human thyrotr
record-and-verify systems
Rectal adenocarcinoma
Rectal cancer
rectal fistula
rectal injury
Rectal lymphomas
rectal neoplasms
Rectovaginal fistula
Rectovaginal septum
Rectum
rectus abdominis muscle
Recurrence
Recurrent
Recurrent carcinoma
Recurrent high-grade glio
recurrent ovarian cancer
Recurrent rectal carcinom
Reflux esophagitis
Regional chemotherapy
regional medical programs
Regional program
registries
regression
regression analysis
reirradiation
Relapse
relative survival
relative value
Renal cancer
Renal carcinoma
Renal cell cancer
Renal cell carcinoma
Renal failure
Renal metastasis
renal osteosarcoma
renal papillary carcinoma
Renomedullary interstitia
Reproductive factors
Resection
residual lesion
Resistant
resources
respiratory failure
RET oncoproteins
Ret tyrosine kinase
RET/PTC
Retinal metastases
retro-orbital granulocyti
Retroperitoneal liposarco
retroperitoneal mass
retroperitoneal tumor
retrorectal hamartoma
retrorectal tumors
retrospective study
review
rewards
rhabdomyosarcoma
Rheumatoid arthritis
rhuCD40L,TRAF
ring and tandem
risk factor
risk factors
Risk of cancer
RNA
RNA interference
Runx2
S-100 protein
s-phase fraction
S-phase fraction.
sacroplasty
Salivary gland
Salvage radiotherapy
salvage therapy
Sampling bias
Sarcoma
sarcomatoid renal cell ca
Sarcomatosis
Scalene lymph node
scalp
scalp cooling
Schwann cell
Schwannoma
SCID mice
Sclerosing hemangioma
Scoring
Screening
seasonality
Second line
Second malignancies
second primary cancer
second primary tumors
second-hand smoke
second-line
Second-line chemotherapy
secondary breast angiosar
secondary hemicolectomy
Secondary malignancies
secondary prevention
Secondary sarcomas
SEER program
Segmental duodenal resect
selection criteria
Selective estrogen recept
selective internal radiat
self-expanding stent
self-report assessment
seminal vesicle invasion
seminoma
Sensitivity
sentinel lymph node
Sentinel lymph node biops
Sentinel lymph node mappi
Sentinel node
Sentinel node mapping
sequence
sequence variant
sequence-specific primer
sequential chemotherapy
serum
Serum lactate dehydrogena
sestamibi
setup uncertainty
sex cord stromal tumor
Sex-specific rates
sexual dysfunction
SF-36 questionnaire
shoe worker
shoulder movement
shoulder syndrome
Signs
Silver staining
simple cholecystectomy
simultaneous care
simultaneous thyroid carc
Single agent
single nucleotide polymor
single nucleotide polymor
single strand conformatio
single-strand conformatio
single-strand conformatio
sinonasal cancer
siRNA
Sister Joseph's nodule
size
skeletal muscle
skin
skin cancer
Skin metastases
Skin neoplasms
skin squamous cell carcin
skin toxicity
Smac/DIABLO
Small bowel
Small cell carcinoma
Small cell lung cancer
Small cell lung carcinoma
Small intestine adenocarc
Small melanocytic skin le
Small melanoma
Small-cell lung cancer
Smoking
smoking ban
Smoking cessation
Smoking habits
social class
Socio-economic data valid
Sodium iodide
soft tissue sarcoma
Soft tissue sarcomas
soft tissue tumor
soft-tissue tumor
solid pseudopapillary neo
solid tumor
solitary fibrous tumor
Solitary plasmacytoma
somatostatin analogs
Somatostatin analogues
Somatostatin receptor sci
Somatostatin receptors
sorafenib
Sox9
Spain
Specificity
Sphincter saving procedur
sphincter-saving procedur
sphincter-saving surgery
spinal accessory nerve
spinal cord
spindle cell
spindle-cell carcinoma
spleen.
Splenectomy
splenic lymphangioma
splenic metastases
Splenic rupture
Splenomegaly
splenopancreasectomy
Spontaneous internal jugu
Squamous cell carcinoma
squamous cell carcinoma a
squamous cell carcinoma o
Squamous cell carcinoma,V
Squamous cell laryngeal c
stage
stage III
Staging
Standard incidence ratio
statistical method.
Statistical model
Stealth liposomes
stem cell transplantation
stenosis
Stereotactic
stereotactic body radiati
stereotactic radiosurgery
Sternberg tumor
Sternum
Steroid receptors
Steroids
Stevens-Johnson syndrome
Stomach
stomach cancer
stool test
stop-flow
Subcutaneous mastectomy
subdural hematoma
Subdural osteomas
Subgroup analysis
Sugar industry
Suicide
Suicide thoughts
sulfur compounds
Sunburn
sunitinib
Superficial therapy
Superior hypogastric plex
superior mediastinal synd
superior vena cava syndro
supernumerary breast
Superoxide dismutase
supraclavicular adenopath
supraclavicular lymphaden
supraclavicular radiother
supraventricular tachycar
Surgery
surgical complications
Surgical margins
surgical mortality
surgical oncology
surgical procedures
Surgical resection
surgical strategy
surgical treatment
Suriname
Survey
Survival
Survival analysis
SV40
Swiss albino mice
Sympathetic cervical chai
Sympathetic chain
Symporter (NIS)
Symptom management
symptom-to-treatment inte
Symptoms
Synaptophysin
synchronous cancer
Synchronous multicentric
Synchronous presentation
synchronous triple cancer
Synchronous tumors
synergistic effect
synovial sarcoma
systemic chemotherapy
T2 signal intensity
Tamoxifen
Tangential irradiation
tanshinone II-A
target coverage
Target delineation
target therapies
target therapy
Target volume
targeted contrast materia
targeted drug delivery
targeting
taxane
Taxol
Taxotere
TCF regimen
tcr-gamma
Technetium-99m
technique investigation
tectal glioma
telemedicine
Telomerase activity
telomerase RNA
Temozolomide
temozolomide refractory
teratoma
terebrant ulcer
terminal cancer patients
terminal patient
terminally ill
test
testicular cancer
Testicular seminoma
Testicular tumors
Testis
Testosterone,Wistar rats
tetrandrine
thalidomide
Therapeutic guidelines
therapeutic strategies
therapy
therapy-related leukemia
thiamine
Thiols
third-line chemotherapy
Three-dimensional conform
three-dimensional conform
Thrombocytopenia
thrombophilic screening
Thrombosis
Thrombotic thrombocytopen
Thymic carcinoid
thymolipoma
Thymoma
thymus
Thyroglobulin
Thyroglobulin (Tg)
Thyroglossal duct cyst
Thyroglossal duct remnant
Thyroid
Thyroid cancer
Thyroid cancer scintigrap
Thyroid carcinoma
thyroid gland
thyroid lesions
thyroid metastases
thyroid metastasis
Thyroid neoplasms
thyroid nodule
thyroid squamous cell car
thyroid surgery
thyroid tumor
thyroidectomy
time trends
Time-intensity dynamic pr
TIMP3
Tissue remodelling
tobacco
Tobacco smoking
tomotherapy
Tongue
tongue cancer
tonsil
tonsil metastasis
topoisomerase IIa
total colectomy
Total dermatoscopic score
total gastrectomy
total parental nutrition
Toxicity
TP53
TPS commissioning
TRAIL
training
tram
transanal excision
Transarterial chemoemboli
transcatheter arterial ch
Transitional cell carcino
translational research
Transplant-related compli
Transrectal ultrasonograp
transverse colon
trastuzumab
Treatment
Treatment guidelines
treatment monitoring
treatment response predic
treatment verification
Trends
trends in smoking
TRIMprobTM
Triphenylethylenes
triplet
triplet regimen
Trisomy 21
TSPAN1
TTF-1
Tuberculosis
Tumor
tumor and nontumor lesion
tumor bank
tumor burden
tumor cells
Tumor lysis syndrome
Tumor marker
Tumor marker CA 15-3
Tumor markers
tumor metastasis
tumor response
tumor sample
tumor seeding
tumor size
tumor stage
Tumor staging
Tumor-associated mononucl
Tumor-like lesion
tumor-like multiple scler
Tumorigenesis
Tumorlets
Tumors macrophages
Turkish breast cancer sur
tuscany
twins
type-1 neurofibromatosis
Tyrosine kinase
tyrosine kinase inhibitor
ultrasonography
Ultrasound
Ultrasound-guided fine-ne
Umbilical nodule
unconventional cancer tre
undertreatment
undifferentiated esophage
undifferentiated nasophar
uniscale assessment
unknown primary
unknown primary site
unknown primary tumors
unresectable
Unusual metastatic sites
uPA,TIMP
upper aerodigestive cance
Upregulation
Urachal carcinoma
Urbanization
urethane
Urinary bladder metastase
urinary tract
urokinase plasminogen act
urothelial cancer
Urothelial carcinoma
Urothelial carcinoma of t
urothelium.
usage of cam
uterine cervical cancer
uterine cervix cancer
uterine cervix carcinoma
uterine metastasis
Uterine neoplasms
Uterine sarcoma
uterine serous cancer
Uterus
Uveal melanoma
UW-QOL
Vaccination
Vacuum-assisted core biop
Vaginal cancer
validation
validity
Vascular endothelial grow
vascular proliferation
Vascular tumor
vascular tumors
VE-cadherin,VEGF
vectorization
Venous thromboembolic com
Vertebral compression fra
Vertebral tumor
vertebroplasty
videoconference
Vinblastine
Vinorelbine
virtual bio repository
vitamin A
Vitamin D analogs
VM26
vocal fold paralysis
vocal folds
voice disorder
VP3
Weekly administration
Weekly docetaxel
weekly docetaxel and gemc
Weekly paclitaxel therapy
Weekly therapy
Wernicke's encephalopath
WHO histopathological cla
whole abdominal irradiati
whole brain radiotherapy
wnt signaling
Wnt-5a
women
Woringer-Kolopp disease
X-ray computed tomography
X-rays
Xenograft
yolk sac tumor
young
youth smoking
yttrium-90
-------------------------------